Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

nL-ATN1-002

PreclinicalSmall molecule

Nn-Lorem Foundation

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dentatorubral-Pallidoluysian AtrophyActive, not recruiting

Dentatorubral-Pallidoluysian AtrophyPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Dentatorubral-Pallidoluysian Atrophy

NCT07084311

Clinical

Trials by Indication[1]

ART1 trial

Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation

Active, not recruiting·Nn-Lorem Foundation·Phase 1/2·NCT06706388·1 enrolled

Dentatorubral-Pallidoluysian Atrophy1 trial

An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for ATN1 Mutation Associated Dentatorubral-pallidoluysian Atrophy (DRPLA)

Active, not recruiting·Nn-Lorem Foundation·Preclinical·NCT07084311·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for nL-ATN1-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nL-ATN1-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nL-ATN1-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — n-Lorem Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Nn-Lorem Foundation

Related News